Patents by Inventor Jean-Marc Roch
Jean-Marc Roch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090087436Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.Type: ApplicationFiled: September 27, 2007Publication date: April 2, 2009Applicant: Myriad Genetics, IncorporatedInventors: Jean-Marc Roch, Karen Heichman
-
Publication number: 20070225209Abstract: The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.Type: ApplicationFiled: January 31, 2007Publication date: September 27, 2007Applicant: Myriad Genetics, IncorporatedInventors: Jean-Marc Roch, Paul Bartel, Karen Heichman
-
Patent number: 7229779Abstract: A variant human ?7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human ?7 nAChR. Nucleic acid molecules encoding the variant human ?7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.Type: GrantFiled: December 30, 2003Date of Patent: June 12, 2007Assignee: Abbott LaboratoriesInventors: Clark A. Briggs, Murali Gopalakrishnan, David G. Mc Kenna, Lisa M. Monteggia, Jean-Marc Roch, James P. Sullivan, Edward Touma
-
Publication number: 20070087363Abstract: The invention provides methods of treating, preventing, delaying the onset, slowing the progression, or reversing the symptoms of Alzheimer's disease and other neurodegenerative diseases characterized by the accumulation of amyloid plaques comprising the A?42 peptide. The invention also provides compounds that reduce the production or secretion of the A?42-peptide by cells, and pharmaceutical compositions comprising such compounds, for the treatment of neurodegenerative diseases characterized by the accumulation of amyloid plaques comprising the A?42 peptide.Type: ApplicationFiled: September 18, 2006Publication date: April 19, 2007Applicant: Myriad Genetics, IncorporatedInventors: Paul Bartel, Jean-Marc Roch, Janice Sugiyama
-
Patent number: 7015015Abstract: The present invention provides an isolated or purified polynucleotide that encodes human endosulfine polypeptide. Isoforms of human endosulfine are also disclosed. The invention also provides methods of making recombinant human endosulfine using the polynucleotides and host cells transformed with the polynucleotides.Type: GrantFiled: April 2, 2001Date of Patent: March 21, 2006Assignee: Abbott LaboratoriesInventors: Jean-Marc Roch, Victoria E. S. Scott, Kristi L. Anderson, James P. Sullivan
-
Publication number: 20050171207Abstract: The invention provides compositions and methods for treating neurodegenerative disorders. The method of the invention involves administering to an individual in need of treatment a composition having an R—NSAID and an HMG-CoA reductase inhibitor. The methods and compositions of the invention are useful for treating and preventing neurodegenerative disorders like Alzheimer's disease, dementia, mild cognitive impairment.Type: ApplicationFiled: March 28, 2005Publication date: August 4, 2005Applicant: Myriad Genetics, IncorporatedInventors: Adrian Hobden, Jean-Marc Roch
-
Publication number: 20040226056Abstract: The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.Type: ApplicationFiled: February 9, 2004Publication date: November 11, 2004Applicant: Myriad Genetics, IncorporatedInventors: Jean-Marc Roch, Paul Bartel, Karen Heichman
-
Publication number: 20040203033Abstract: A variant human &agr;7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human &agr;7 nAChR. Nucleic acid molecules encoding the variant human &agr;7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.Type: ApplicationFiled: December 30, 2003Publication date: October 14, 2004Inventors: Clark A. Briggs, Murali Gopalakrishnan, David G. Mc Kenna, Lisa M. Monteggia, Jean-Marc Roch, James P. Sullivan, Edward Touma
-
Patent number: 6683157Abstract: A variant human &agr;7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human &agr;7 nAChR. Nucleic acid molecules encoding the variant human &agr;7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.Type: GrantFiled: September 18, 2001Date of Patent: January 27, 2004Assignee: Abbott LaboratoriesInventors: Clark A. Briggs, Murali Gopalakrishnan, David G. Mc Kenna, Lisa M. Monteggia, Jean-Marc Roch, James P. Sullivan, Edward Touma
-
Patent number: 6653102Abstract: The present invention relates to the discovery of protein—protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.Type: GrantFiled: October 11, 2001Date of Patent: November 25, 2003Assignee: Myriad Genetics, Inc.Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman, Kimberly Mauck, Max Dufford
-
Publication number: 20030186317Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.Type: ApplicationFiled: October 9, 2001Publication date: October 2, 2003Applicant: Myriad Genetics, Inc.Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
-
Publication number: 20030073161Abstract: A variant human &agr;7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human &agr;7 nAChR. Nucleic acid molecules encoding the variant human &agr;7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.Type: ApplicationFiled: September 18, 2001Publication date: April 17, 2003Inventors: Clark A. Briggs, Murali Gopalakrishnan, David G. McKenna, Lisa M. Monteggia, Jean-Marc Roch, James P. Sullivan, Edward Touma
-
Publication number: 20020164655Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.Type: ApplicationFiled: October 11, 2001Publication date: November 7, 2002Applicant: Myriad Genetics, Inc.Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
-
Publication number: 20020142432Abstract: The present invention provides an isolated or purified polynucleotide that encodes human endosulfine polypeptide. Isoforms of human endosulfine are also disclosed. The invention also provides methods of making recombinant human endosulfine using the polynucleotides and host cells transformed with the polynucleotides.Type: ApplicationFiled: April 2, 2001Publication date: October 3, 2002Inventors: Jean-Marc Roch, Victoria E.S. Scott, Kristi L. Anderson, James P. Sullivan
-
Publication number: 20020124273Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.Type: ApplicationFiled: October 11, 2001Publication date: September 5, 2002Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
-
Publication number: 20020119155Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.Type: ApplicationFiled: October 9, 2001Publication date: August 29, 2002Applicant: Myriad Genetics, Inc.Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
-
Publication number: 20020119927Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.Type: ApplicationFiled: October 9, 2001Publication date: August 29, 2002Applicant: Myriad Genetics, Inc.Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
-
Publication number: 20020120947Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.Type: ApplicationFiled: September 10, 2001Publication date: August 29, 2002Applicant: Myriad Genetics, Inc.Inventors: Jean-Marc Roch, Paul L. Bartel
-
Publication number: 20020115607Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.Type: ApplicationFiled: October 12, 2001Publication date: August 22, 2002Applicant: Myriad Genetics, Inc.Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman
-
Publication number: 20020114799Abstract: The present invention relates to the discovery of protein-protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.Type: ApplicationFiled: October 10, 2001Publication date: August 22, 2002Applicant: Myriad Genetics, Inc.Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman